What is the recommended treatment for neuropathic ocular itch and pain?

Treatment of Neuropathic Ocular Itch and Pain

For neuropathic ocular pain and itch, initiate first-line systemic therapy with nortriptyline 10-25 mg at bedtime (titrating to 25-100 mg) or carbamazepine 200 mg nightly (titrating to 400-1200 mg daily in divided doses), combined with topical neuro-regenerative agents including preservative-free autologous serum tears and anti-inflammatory therapy. 1

Algorithmic Treatment Approach

Step 1: Confirm Neuropathic Component

• Pain/itch disproportionate to clinical findings on slit-lamp examination
• Minimal corneal staining despite severe symptoms
• Symptoms include burning, photophobia, or persistent discomfort
• Consider proparacaine challenge testing to distinguish neuropathic from nociceptive pain 2

Step 2: Immediate Topical Management (All Patients)

Mandatory interventions:

• Discontinue ALL preservative-containing eye drops immediately 3
• Preservative-free artificial tears, gels, or ointments 1, 3
• Autologous serum tears 20% or umbilical cord serum/platelet-rich plasma drops 1, 3
• Punctal occlusion 3

Additional topical options:

• Cyclosporine 0.05% for anti-inflammatory effect 2
• Tacrolimus eye drops 4
• Rebamipide eye drops for neuro-regeneration 4

Step 3: First-Line Systemic Pharmacotherapy

The evidence strongly supports two primary agents based on randomized controlled trials in post-herpetic neuralgia and trigeminal neuralgia:

Option A: Nortriptyline (Preferred due to superior side effect profile) 1

• Start: 10-25 mg at bedtime
• Titrate: Increase every 3-7 days
• Target: 25-100 mg at bedtime
• Mechanism: Inhibits serotonin/norepinephrine reuptake, blocks sodium channels
• Side effects: Dry mouth, constipation, sedation
• Evidence: 66% pain reduction in 3 weeks in PHN trials 1

Option B: Carbamazepine 1

• Start: 200 mg at night
• Titrate: Increase by 200 mg every 7 days
• Target: 400-1200 mg daily in 2-3 divided doses
• Mechanism: Sodium channel blocker
• Evidence: Level A recommendation for trigeminal neuralgia; 70% achieved partial/complete relief 1
• Side effects: Drowsiness, headache, dizziness

Step 4: Alternative Systemic Agents

For refractory cases or when first-line agents fail:

• Gabapentin or Pregabalin (alpha-2-delta ligands) 5, 4, 2
  • Mirogabalin specifically showed efficacy in Sjögren's-related neuropathic ocular pain 4
• Low-dose naltrexone 5
• Novel agents under investigation:
  • Difelikefalin (κ-opioid receptor agonist) for neuropathic itch 5
  • Libvatrep (TRPV1 antagonist) for neuropathic pain 5

Step 5: Adjunctive Physical Interventions

For moderate-to-severe cases:

• Therapeutic soft contact lenses or scleral lenses (PROSE) for immediate symptom relief by shielding corneal nociceptors 1
  • Caveat: May worsen symptoms in patients with severe hyperalgesia where lenses provide noxious stimuli 1
• Fresh-frozen self-retained amniotic membrane 3

For advanced/refractory cases:

• Tarsorrhaphy 3
• Corneal neurotization 3
• Non-invasive neurostimulation (transcutaneous electrical nerve stimulation, transcranial magnetic stimulation) 6
• Periorbital quantum molecular resonance electrotherapy 2

Step 6: Address Underlying Causes

Critical evaluation for:

• Herpetic eye disease → antiviral therapy 3
• Blepharospasm → botulinum toxin injections 2
• Systemic inflammatory conditions (Sjögren's syndrome, diabetes) → optimize systemic control 3, 4
• Meibomian gland dysfunction → treat accordingly 3
• Neurotoxic systemic medications (neuroleptics, antipsychotics, antihistamines) → discontinue if possible 3

Key Clinical Pearls

Combination therapy is often necessary rather than monotherapy, particularly when central sensitization is present 1. The 2017 Ophthalmology guidelines explicitly state that systemic pharmacotherapy is required when central sensitization drives symptoms 1.

Co-management consideration: Ophthalmologists unfamiliar with systemic neuromodulators should initially co-manage with neuropathic pain specialists, then transition to independent management as experience grows 1.

Timing matters: Earlier initiation of tricyclic antidepressants correlates with better outcomes in post-herpetic neuralgia 1, suggesting prompt treatment is critical.

Distinguish neuropathic itch from pain: While both arise from polymodal nerve activation, neuropathic itch may respond better to κ-opioid receptor agonists, whereas neuropathic pain may respond to TRPV1 antagonists 5.

Common Pitfalls

• Continuing preservative-containing drops perpetuates corneal nerve damage 3
• Treating only the ocular surface when central sensitization requires systemic therapy 1
• Delaying systemic pharmacotherapy in patients with pain disproportionate to findings 4
• Missing systemic inflammatory exacerbations (e.g., Sjögren's flares) that worsen neuropathic pain independent of ocular surface findings 4